Shareholders of the Irish drug maker, which has its U.S. base in Hazelwood, and its Pennsylvania-based merger target have ...

DUBLIN and MALVERN, Pa., March 13, 2025/ PRNewswire/-- Mallinckrodt plc and Endo, Inc. today announced that they have entered into a definitive agreement to combine in a stock and cash transaction ...

Endo's initial capital structure is expected to consist of a $400.0 million senior secured five-year super-priority revolving credit facility (undrawn at emergence), a $1,500.0 million senior ...

Mallinckrodt and Endo announced that their respective shareholders have provided the necessary shareholder approvals for the ...

DUBLIN, Ireland & MALVERN, PA — Mallinckrodt plc and Endo, Inc. (OTCQX: NDOI) have detailed the senior leadership structure for their anticipated merger, a move aimed at creating a global … ...

Overall, 16 suspect lots have been implicated in the latest generic clonazepam pull. The batches in question contain 0.125-mg, 0.25-mg, 1-mg and 2-mg doses of the drug and were shipped out to ...

Mallinckrodt and Endo announced the future executive team that will drive the creation of global, scaled, diversified therapeutics company in both the branded specialty pharmaceuticals and the ...

Clonazepam Orally Disintegrating Tablets, USP 0.125mg, Lot# 550147301, expiration date August 2026. At this time, there have been no reports of adverse reactions related to this recall.

Mallinckrodt PLC, an Irish pharmaceutical company with a big footprint and long history in the St. Louis area, will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion.

Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company"), a diversified specialty pharmaceutical company transforming insights into life-enhancing therapies, today announced that the U.S. Securities and ...

MALVERN, Pa., June 17, 2025 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI) today announced that it has completed the previously announced divestiture of its International ...